Abstract
AbstractThe establishing of the first cancer models created a new perspective on the identification and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft models are created by tumor tissue engraftment. These models accurately represent the biology and heterogeneity of different cancers and recapitulate tumor microenvironment. These features have made it a reliable model along with the development of humanized models. Therefore, they are used in many studies, such as the development of anti-cancer drugs, co-clinical trials, personalized medicine, immunotherapy, and PDX biobanks. This review summarizes patient-derived xenograft models development procedures, drug development applications in various cancers, challenges and limitations.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference147 articles.
1. Pott P. Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes and feet, by Percivall Pott, FRS Surgeon to St. Bartholomew’s-Hospital. Printed, by TJ Carnegy, For L. Hawes, W. Clarke, and R. Collins, in Pater-noster Row; 1775.
2. Hedrich HJ. The house mouse as a laboratory model: a historical perspective. The Laboratory Mouse. Burlington: Elsevier Science; 2012. p. 868.
3. Johnson J, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424–31.
4. Ellis LM, Fidler IJ. Finding the tumor copycat: therapy fails, patients don’t. Nat Med. 2010;16(9):974–5.
5. Rezaee R, Abdollahi M. The importance of translatability in drug discovery. Expert Opin Drug Discov. 2017;12(3):237–9.
Cited by
70 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献